Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
john eisenbrey
Study ID
NCT05641935
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Sulfur Hexafluoride Lipid Microspheres — DRUG
    Given IV
  • Contrast-Enhanced Ultrasound — PROCEDURE
    Undergo CEUS
  • Computed Tomography — PROCEDURE
    Undergo CT
  • Magnetic Resonance Imaging — PROCEDURE
    Undergo MRI
  • Electronic Health Record Review — OTHER
    Review electronic medical record

Study Details

This phase II trial studies how well contrast-enhanced ultrasound (CEUS) works for diagnosing patients with renal cell cancer (RCC) that has come back (recurrent) after an ablation. Diagnostic imaging, such as CEUS, may help find and monitor long term renal cell cancer recurrence following cryo or microwave ablation.

Key Dates

Start date
Nov 3, 2022
Status verified
Feb 2026
Primary completion
Aug 31, 2027
Completion
Aug 31, 2027

Study Design

Enrollment
210 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Diagnostic (CEUS with MRI/CT)
    Patients receive Lumason IV and undergo CEUS imaging with MRI/CT on study. Patients' electronic medical record is reviewed every 6 months throughout study.

Primary Outcome Measure

Renal cell carcinoma recurrence [ Time Frame: Up to 2 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Sidney Kimmel Cancer Center at Thomas Jefferson UniversityPhiladelphiaPennsylvania19107
John Eisenbrey, MD
[email protected]

Find similar trials in Philadelphia, PA

By condition
Kidney cancer
By specialty
OncologyUrology
By research site
Sidney Kimmel Cancer Center at Thomas Jefferson University· Philadelphia, PA

Related Studies